LipoCol and Mevacor — Competitive Intelligence Brief

LipoCol and Mevacor (LipoCol and Mevacor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HMG-CoA reductase inhibitor (statin). Area: Cardiovascular.

marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase Cardiovascular Small molecule

Target snapshot

LipoCol and Mevacor (LipoCol and Mevacor) — Taipei Medical University WanFang Hospital. LipoCol and Mevacor are statins that inhibit HMG-CoA reductase to reduce cholesterol synthesis in the liver.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LipoCol and Mevacor TARGET	LipoCol and Mevacor	Taipei Medical University WanFang Hospital	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
atorvastatin, aspirin, losartan, amlodipine	atorvastatin, aspirin, losartan, amlodipine	Russian Cardiology Research and Production Center	marketed	Fixed-dose combination: HMG-CoA reductase inhibitor, antiplatelet agent, angiotensin II receptor antagonist, and calcium channel blocker	Multiple: HMG-CoA reductase, cyclooxygenase, AT1 receptor, L-type calcium channel
Atorvastatin and fenofibrate	Atorvastatin and fenofibrate	The University of Western Australia	marketed	Statin and fibrate combination	HMG-CoA reductase and PPAR-α

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2037-06-07 — Lipitor · 11654106 · US
• 2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (HMG-CoA reductase inhibitor (statin) class)

1. Organon and Co · 7 drugs in this class
2. Kuhnil Pharmaceutical Co., Ltd. · 3 drugs in this class
3. Wenzhou Medical University · 2 drugs in this class
4. Amgen · 2 drugs in this class
5. Beijing Tiantan Hospital · 2 drugs in this class
6. Seoul National University Hospital · 2 drugs in this class
7. JW Pharmaceutical · 2 drugs in this class
8. AstraZeneca · 2 drugs in this class
9. Korea University Anam Hospital · 2 drugs in this class
10. Gachon University Gil Medical Center · 1 drug in this class